喹啉-6-硼酸 | 376581-24-7

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 喹啉-6-硼酸
• 中文别名: 6-喹啉硼酸
• 英文名称: 6-quinolineboronic acid
• 英文别名: quinolin-6-ylboronic acid；quinoline-6-boronic acid；6-quinolylboronic acid
• CAS: 376581-24-7
• 化学式: C₉H₈BNO₂
• mdl: MFCD03093100
• 分子量: 172.979
• InChiKey: JLOLSBLXNMVKGY-UHFFFAOYSA-N

物化性质

• 熔点：
  106-109°C
• 沸点：
  400.3±37.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.09
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  Keep Cold

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Quinoline-6-boronic acid
Product Name:
Synonyms: Quinolin-6-ylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Quinoline-6-boronic acid
Ingredient name:
CAS number: 376581-24-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H8BNO2
Molecular weight: 173.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  喹啉-6-硼酸 在 N,N-二异丙基乙胺 作用下， 以 重水 、 乙腈 为溶剂， 反应 24.0h， 生成 6-羟基喹啉
  参考文献：
  名称：

  富电子共价有机骨架COF-JLU25在芳基硼酸光催化有氧氧化羟基化制备苯酚中的应用

  摘要：

  COF-JLU25，一COF -基于光催化剂仅由供电子单元，1,3,6,8-四（4-氨基苯基）芘（PyTA）和4- [4-（4-甲酰基甲基）-2,5- -二甲氧基苯基]苯甲醛（TpDA）在用于催化芳基硼酸的氧化羟基化时表现出优异的光催化活性，具有高效率、稳健的可重复使用性和低催化剂负载。

  DOI：

  10.1002/ejoc.202100173
• 作为产物：
  描述：

  6-溴喹啉 在 四羟基二硼 、 1,3-bis[(diphenylphosphino)propane]dichloronickel(II) 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 喹啉-6-硼酸
  参考文献：
  名称：

  镍催化四羟基二硼 [B2(OH)4] 卤化物和拟卤化物的硼化反应

  摘要：

  芳基硼酸作为试剂和目标结构在各种有用的应用中变得越来越重要。最近，报道了使用原子经济的四羟基二硼（BBA）试剂在钯催化下合成芳基硼酸。钯的高成本，加上钯和铜催化工艺的一些限制，促使我们开发一种替代方法。因此，已经制定了使用四羟基二硼（BBA）对芳基和杂芳基卤化物和拟卤化物进行镍催化的硼基化反应。该反应被证明具有广泛的官能团耐受性并适用于许多杂环体系。据我们所知，这里提供的例子代表了在室温下进行的唯一有效的镍催化宫浦硼化反应。

  DOI：

  10.1021/jo401104y

文献信息

• [EN] ANTI-CANCER AND ANTI-HIV COMPOUNDS<br/>[FR] COMPOSÉS ANTICANCÉREUX ET ANTI-VIH
  申请人：SIRENAS MARINE DISCOVERY

  公开号：WO2014123900A1

  公开（公告）日：2014-08-14

  Disclosed herein are compounds useful as anti-cancer and anti-HIV agents. Also disclosed are pharmaceutical compositions and methods of treatment. The compounds disclosed herein can be used to treat a variety of conditions, diseases and ailments such as bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, lung cancer, melanoma, non-Hodgkin lymphoma, glioblastoma, pancreatic cancer, prostate cancer, and thyroid cancer, and HIV related disorders.

  本文披露了作为抗癌和抗HIV药物有用的化合物。还披露了药物组合物和治疗方法。本文披露的化合物可用于治疗多种疾病和疾病，如膀胱癌、乳腺癌、结肠癌、直肠癌、子宫内膜癌、肾癌、肺癌、黑色素瘤、非霍奇金淋巴瘤、胶质母细胞瘤、胰腺癌、前列腺癌和甲状腺癌，以及HIV相关疾病。
• 一种铜催化的芳基硼酸与二氧化碳的羧化反 应方法
  申请人：北京大学

  公开号：CN110577457B

  公开（公告）日：2021-02-02

  本发明公开了一种铜催化的芳基硼酸与二氧化碳的羧化反应方法。该方法使用二氧化碳作为C1源，采用铜催化，醇盐作为碱在有机溶剂中反应，简单易行，并且表现出广泛的官能团相容性，使单或多取代苯基硼酸、多环芳烃类硼酸或苯并杂环类硼酸等各种芳基硼酸可以在较温和条件下转化为相应的芳基羧酸，具有相当可观的产率。所得产物羧酸本身具有重要的应用价值，而且可以衍生出不少常见的其他化学物质，如酰卤、酸酐、酯和酰胺等。
• Modular Synthesis of Di- and Trisubstituted Imidazoles from Ketones and Aldehydes: A Route to Kinase Inhibitors
  作者：Ian de Toledo、Thiago A. Grigolo、James M. Bennett、Jonathan M. Elkins、Ronaldo A. Pilli

  DOI：10.1021/acs.joc.9b01844

  日期：2019.11.1

  A one-pot and modular approach to the synthesis of 2,4(5)-disubstituted imidazoles was developed based on ketone oxidation, employing catalytic HBr and DMSO, followed by imidazole condensation with aldehydes. This methodology afforded twenty-nine disubstituted NH-imidazoles (23%-85% yield). A three-step synthesis of 20 kinase inhibitors was achieved by employing this oxidation-condensation protocol

  基于酮氧化，采用催化HBr和DMSO，然后通过咪唑与醛的缩合反应，开发了一种单罐模块化方法，用于合成2,4（5）-二取代的咪唑。该方法提供了二十九个二取代的NH-咪唑（23％-85％的产率）。通过采用这种氧化-缩合方案，然后在咪唑环中进行溴化和Suzuki偶联，得到三取代的NH-咪唑（23％-69％，三步法），实现了三步合成20种激酶抑制剂的过程。该方法还用于合成已知抑制剂GSK3037619A。
• Structure−Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine (PBD) Antitumor Agents
  作者：Dyeison Antonow、Maciej Kaliszczak、Gyoung-Dong Kang、Marissa Coffils、Arnaud C. Tiberghien、Nectaroula Cooper、Teresa Barata、Sibylle Heidelberger、Colin H. James、Mire Zloh、Terence C. Jenkins、Anthony P. Reszka、Stephen Neidle、Sylvie M. Guichard、Duncan I. Jodrell、John A. Hartley、Philip W. Howard、David E. Thurston

  DOI：10.1021/jm901722v

  日期：2010.4.8

  comprehensive SAR investigation of the C2-position of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) monomer antitumor agents is reported, establishing the molecular requirements for optimal in vitro cytotoxicity and DNA-binding affinity. Both carbocyclic and heterocyclic C2-aryl substituents have been studied ranging from single aryl rings to fused ring systems, and also styryl substituents, establishing across

  吡咯烷[2,1- c]的C2位的SAR综合研究] [1,4]苯并二氮杂（PBD）单体抗肿瘤药物的报道，建立了最佳的体外细胞毒性和DNA结合亲和力的分子要求。碳环和杂环C2-芳基取代基的研究范围从单个芳基环到稠环系统，还有苯乙烯基取代基，在80个类似物库中建立，C2-芳基和苯乙烯基取代基可显着增强DNA结合亲和力和体外细胞毒性，两者之间具有相关性。发现DNA结合亲和力和细胞毒性的最佳C2分组是C2-喹啉基部分，根据分子模型，这是由于分子在DNA小沟中的整体适合性以及与功能性分子的潜在特异性接触所致。组在凹槽的地板和墙壁中。这个类似物（在HCT-116（bowel）人肿瘤异种移植模型中显示了14l）延迟肿瘤生长。
• [EN] BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS<br/>[FR] COMPOSITIONS DE BENZOPIPÉRAZINE EN TANT QU'INHIBITEURS DE BROMODOMAINES BET
  申请人：BAIR KENNETH W

  公开号：WO2015074081A1

  公开（公告）日：2015-05-21

  The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.

  本发明涉及用于治疗癌症、炎症性疾病、糖尿病和肥胖的溴和末端（BET）溴结构域抑制剂，具有公式（I）：其中X、Y、Z、R1、R2、R4和R7的定义如下。